Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (114)	12/19/2003 11:11:53 AM
From: keokalani'nui	Respond to of 12215

But Acorda Therapeutics (ACRD: news, chart, profile) said late Thursday it is postponing its initial public offering due to current market conditions, according to Dealogic, a global data research firm that tracks IPO activity. The Hawthorne, N.Y.-based biotech firm was planning to offer 4.8 million shares at $12-$14 each in a bid to raise up to $67 million with underwriter Banc of America Securities. There was no one immediately available at Acorda for comment.